Trial Profile
Phase II Study of Capecitabine, Oxaliplatin and Cetuximab Given Throughout Multi-Modal Therapy for Locally Advanced Rectal Adenocarcinoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Cetuximab (Primary) ; Oxaliplatin (Primary)
- Indications Adenocarcinoma; Rectal cancer
- Focus Therapeutic Use
- 25 Jun 2019 Status changed from completed to discontinued.
- 23 Sep 2016 Planned number of patients changed from 40 to 6.
- 23 Sep 2016 Status changed from discontinued to completed.